|Mr. Osamu Nagayama||Chairman||N/A||N/A||1947|
|Mr. Tatsuro Kosaka||Pres, CEO & Representative Director||N/A||N/A||1953|
|Mr. Motoo Ueno||Deputy Chairman||N/A||N/A||N/A|
|Mr. Toshiaki Itagaki||EVP, CFO and GM of Fin. Supervisory Division, Fin. & Accounting Dept.||N/A||N/A||N/A|
|Mr. Junichi Ebihara||Sr. VP & GM of Legal Department||N/A||N/A||N/A|
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Akynzeo, and Aloxi; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, Bonviva, and Alfarol; renal diseases consist of Mircera, Oxarol and Epogin; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, Pegasys, Sigmart, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd.; and collaborative research agreement with Anaeropharma Science Inc. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding AG.
Chugai Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of June 25, 2019 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 1.